OptimizeRx (NASDAQ:OPRX) 株価情報

OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

OptimizeRx Corp

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $8.75, along with a high estimate of $16.00 and a low estimate of $5.00. Observing a downward trend, the current average is 32.69% lower than the prior average price target of $13.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738864823_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Neil Chatterji</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$5.50</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OptimizeRx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for OptimizeRx's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of OptimizeRx's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OptimizeRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know OptimizeRx Better</h2>
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
<h3>Unraveling the Financial Story of OptimizeRx</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 30.48% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: OptimizeRx's net margin is impressive, surpassing industry averages. With a net margin of -42.82%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.75%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): OptimizeRx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.4%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: OptimizeRx's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OPRX

Where OptimizeRx Stands With Analysts

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Market Outperform and maintains $8 price target.

News

Price Target

Reiteration

JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $8 Price Target

WIIM

OptimizeRx shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform and cut its price target from $7 to $6.

RBC Capital analyst Sean Dodge downgrades OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) from Outperform to Sector Perform and lowers the price target from $7 to $6.

Downgrades

RBC Capital Downgrades OptimizeRx to Sector Perform, Lowers Price Target to $6

Lake Street analyst Eric Martinuzzi reiterates OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and maintains $11 price target.

Lake Street Reiterates Buy on OptimizeRx, Maintains $11 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>DA Davidson cut Winnebago Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) price target from $55 to $54. DA Davidson analyst Brandon Rolle maintained a Neutral rating. Winnebago shares closed at $47.99 on Monday. See how other analysts view this stock.</li>
<li>Evercore ISI Group cut the price target for Regency Centers Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>) from $78 to $77. Evercore ISI Group analyst Steve Sakwa maintained an In-Line rating. Regency Centers shares closed at $73.75 on Monday. See how other analysts view this stock.</li>
<li>Telsey Advisory Group lowered the price target for Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) from $26 to $24. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Nordstrom shares closed at $24.17 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for BTCS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) from $3 to $5. HC Wainwright &amp; Co. analyst Kevin Dede maintained a Buy rating. BTCS shares closed at $2.47 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs boosted CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $372 to $415. Goldman Sachs analyst Gabriela Borges maintained a Buy rating. CrowdStrike shares settled at $361.50 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group cut Brixmor Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) price target from $32 to $31. Evercore ISI Group analyst Samir Khanal maintained an In-Line rating. Brixmor Property shares closed at $27.53 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson slashed Destination XL Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) price target from $3.5 to $3. DA Davidson analyst Michael Baker maintained a Buy rating. Destination XL shares closed at $2.61 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods raised the price target for Berkshire Hills Bancorp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) from $32 to $34.5. Keefe, Bruyette &amp; Woods analyst Christopher O&#8217;Connell maintained a Market Perform rating. Berkshire Hills Bancorp shares settled at $28.60 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities cut OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) price target from $17 to $13. B. Riley Securities analyst Neil Chatterji maintained a Buy rating. OptimizeRx shares closed at $4.83 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Enanta Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) price target from $27 to $18. HC Wainwright &amp; Co. analyst Ed Arce maintained a Buy rating. Enanta Pharmaceuticals shares closed at $6.37 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Markets

Trading Ideas

BHLB

BTCS

CRWD

DXLG

ENTA

CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday

B. Riley Securities analyst Neil Chatterji maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and lowers the price target from $17 to $13.

B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $13

<a href="https://www.globenewswire.com/Tracker?data=3IO2gUzW7Cw-Q-FQqDZQbgLiiQ15aDUo_4CXaPHofKgijz46bDoLlvDH-Fk4Z6ygMULR9uH-DRpTw3HQ5bSqk1TB6EK6oPj8GjxiZBN4BQc=">OptimizeRx Corp.</a> (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.

Management

OptimizeRx CEO William Febbo To Depart, Announces Appointment Of Stephen Silvestro As Interim CEO, Effective As Of December 31, 2024

Ratings for OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $8.25, along with a high estimate of $16.00 and a low estimate of $5.00. A 44.26% drop is evident in the current average compared to the previous average price target of $14.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1734717610_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive OptimizeRx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$5.50</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Richard Baldry</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OptimizeRx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of OptimizeRx's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OptimizeRx's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OptimizeRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind OptimizeRx</h2>
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
<h3>OptimizeRx's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 30.48% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching -42.82%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): OptimizeRx's ROE stands out, surpassing industry averages. With an impressive ROE of -7.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): OptimizeRx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.4%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: OptimizeRx's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts

Stephens &amp; Co. analyst Jeff Garro initiates coverage on OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Equal-Weight rating and announces Price Target of $5.5.

Initiation

Stephens & Co. Initiates Coverage On OptimizeRx with Equal-Weight Rating, Announces Price Target of $5.5

<h3>Gainers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) shares moved upwards by 33.8% to $6.69 during Thursday's pre-market session. The market value of their outstanding shares is at $59.4 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares moved upwards by 18.3% to $0.39. The company's market cap stands at $2.4 million. As per the press release, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 16.98% to $0.39. The company's market cap stands at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 16.23% to $3.58. The company's market cap stands at $126.2 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 13.01% to $1.12. The company's market cap stands at $7.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares increased by 11.96% to $11.88. The company's market cap stands at $670.3 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares fell 52.4% to $5.08 during Thursday's pre-market session. The company's market cap stands at $98.1 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 23.08% to $1.8. The company's market cap stands at $47.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 22.77% to $4.75. The company's market cap stands at $87.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares fell 19.79% to $2.21. The company's market cap stands at $81.3 million. The company's, Q3 earnings came out today. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares decreased by 18.92% to $42.0. The company's market cap stands at $1.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 17.76% to $2.78. The market value of their outstanding shares is at $32.4 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADIL

ATXS

CLDI

FBLG

HROW

ICAD

NVCT

PDSB

TIVC

VERO

12 Health Care Stocks Moving In Thursday's Pre-Market Session

RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Outperform and lowers the price target from $14 to $7.

RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $7

Roth MKM analyst Richard Baldry reiterates OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and lowers the price target from $20 to $16.

Roth MKM Reiterates Buy on OptimizeRx, Lowers Price Target to $16

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Buy and lowers the price target from $13 to $8.

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $8

Barclays analyst Stephanie Davis maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Equal-Weight and lowers the price target from $11 to $5.

Barclays Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $5

OptimizeRx shares are trading lower after JMP Securities cut its price target on the stock from $16 to $8.

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Market Outperform and lowers the price target from $16 to $8.

JMP Securities Maintains Market Outperform on OptimizeRx, Lowers Price Target to $8

OptimizeRx shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY24 sales guidance below estimates.

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent. The company reported quarterly sales of $21.309 million which missed the analyst consensus estimate of $24.997 million by 14.76 percent. This is a 30.48 percent increase over sales of $16.331 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

OptimizeRx Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $21.309M Miss $24.997M Estimate

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) sees FY2024 sales of $88.000 million-92.000 million vs $100.69 million estimate.

Guidance

OptimizeRx Sees FY2024 Sales $88.000M-92.000M vs $100.69M Est

Press Releases

General

OptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy Legislation

OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET

OptimizeRx Reports Second Quarter 2024 Financial Results

OptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare Audiences

Health Care

OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value

Comments

OptimizeRx

ニュース

パートナーシップ

ベンジンガ・グローバル